# A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

> **NCT02699606** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 35 (actual)

## Conditions studied

- Neoplasm

## Interventions

- **DRUG:** Erdafitinib

## Key facts

- **NCT ID:** NCT02699606
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-08
- **Primary completion:** 2021-10-12
- **Final completion:** 2024-03-15
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02699606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02699606, "A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT02699606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*